The European Union is seeking to reduce its reliance on China and India for pharmaceutical supplies, aiming to diversify its sources and strengthen domestic production. According to recent reports, the EU is exploring ways to encourage Mexico to increase its own drug manufacturing capabilities. This initiative comes as part of broader efforts to reduce dependency on foreign suppliers, particularly in critical sectors such as medicine and technology.
The push for local production is driven by concerns over supply chain vulnerabilities, especially in light of global geopolitical tensions and the ongoing pandemic. By encouraging countries like Mexico to expand their pharmaceutical output, the EU hopes to create a more resilient and self-sufficient supply network. This strategy would also help reduce the risk of disruptions caused by trade restrictions or geopolitical conflicts.
This move follows a growing trend of economic diversification among major economies. In recent months, several countries have taken steps to reduce their dependence on key suppliers, particularly in the pharmaceutical and technology sectors. The EU’s efforts are part of a larger strategy to ensure stability and security in critical industries. While the details of the plan remain under discussion, the goal is clear: to build a more independent and robust supply chain for essential goods.
